Skip to main
RVTY
RVTY logo

Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity Inc (RVTY) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 27%
Buy 45%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

Revvity has positioned itself for sustained growth following the successful rebranding from PerkinElmer, bolstered by a diversified portfolio that includes high-growth software solutions and a robust life sciences reagents franchise. The company's strategic focus on high-margin segments, such as immunodiagnostics and autoimmune testing, alongside continuous margin improvements driven by operational efficiencies, enhances its financial profile and profitability potential. Furthermore, Revvity's competitive advantages in reimbursement and market expansion in key areas such as the US, Europe, and China underpin a favorable outlook for ongoing revenue growth.

Bears say

Revvity's stock outlook is dampened by declining revenue in its key market of China, particularly within the Immunodiagnostics segment, which reported a double-digit percentage decrease in the second quarter of 2025. This decline contributes to broader concerns regarding customer demand due to poor economic conditions and potential industry funding cuts, negatively impacting growth and market share. Additionally, macroeconomic challenges, such as supply chain disruptions and inflationary pressures, pose risks to Revvity's operational performance and product delivery capabilities.

Revvity Inc (RVTY) has been analyzed by 11 analysts, with a consensus rating of Buy. 27% of analysts recommend a Strong Buy, 45% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Revvity Inc (RVTY) Forecast

Analysts have given Revvity Inc (RVTY) a Buy based on their latest research and market trends.

According to 11 analysts, Revvity Inc (RVTY) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $113.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $113.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Revvity Inc (RVTY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.